Preview

Медицинский Совет

Расширенный поиск

Нимесулид в лечении острой боли в ревматологической практике: почему ниша по-прежнему занята

https://doi.org/10.21518/2079-701X-2016-17-110-112

Полный текст:

Аннотация

В статье изложены данные о возможностях применения нимесулида у пациентов с острой болью, обусловленной поражением опорно-двигательного аппарата. Особенности фармакодинамики, механизмы действия препарата, а также высокий профиль безопасности позволяют рассматривать его в качестве эффективного и быстродействующего средства для купирования острой боли и воспаления. 

Об авторе

М. С. Елисеев
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
к.м.н.


Список литературы

1. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med, 2004, 140: 441-451.

2. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell, 2009, 139: 267-284.

3. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci, 2007, 10: 1361-1368.

4. Dieppe PA, Lohmander LS. Pathogenesis and management of pain in osteoarthritis. Lancet, 2005, 365: 965-973.

5. Arendt-Nielsen L, Nie H, Laursen MB et al. Sensitization in patients with painful knee osteoarthritis. Pain, 2010, 149: 573-581.

6. Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther, 2005, 107: 139-154.

7. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int, 2012, 32: 1491-1502.

8. Sandrini G, Proietti Cecchini A, Alfonsi E et al. Effectiveness of nimesulide in pain. A neurophysiological study in humans. Drugs Today, 2001, 37: 21-29.

9. Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract Suppl, 2002, 128: 11-19.

10. Bernareggi A. Pharmacokinetics of nimesulide. Clin Pharm, 1998, 35(4): 247-274.

11. Bianchi M, Ferrario P, Balzarini P et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res, 2006, 34: 348-354.

12. Binning A. Nimesulide in the treatment of postoperative pain: a double-blind, comparative study in patients undergoing arthroscopic knee surgery. Clin J Pain, 2007, 23: 565-570.

13. Кудаева Ф.М., Елисеев М.С., Барскова В.Г., Насонова В.А. Сравнение скорости наступления анальгетического и противовоспалительного эффектов различных форм нимесулида и диклофенака натрия при подагрическом артрите. Тер. архив, 2007, 5: 35-40.

14. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 2016, 0: 1-14.

15. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs, 2003, 63(Suppl 1): 37-46.

16. Bianchi M, Broggini M, Balzarini P et al. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract, 2007, 61: 1270-1277.

17. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2- selective antiinflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine, 2000, 25: 1579-1585.

18. Wober W, Rahlfs VW, Büchl N et al. Comparative efficacy and safety of the non-steroidal antiinflammatory drugs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J Clin Pract, 1998, 52: 169-175.

19. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and metaanalysis of observational studies (the SOS project). Drug Saf, 2012, 35: 1127-1146.

20. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf, 2013, 22: 365-375.

21. Gulmez SE, Larrey D, Pageaux GP et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf, 2013, 36: 135-144.

22. Venegoni M, Da Cas R, Menniti-Ippolito F et al. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal bleedings in Italy. Ann I-st Super Sanita, 2010, 46(2): 153-157.

23. Helin-Salmivaara A, Virtanen A, Vesalainen R et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J, 2006, 27(14): 1657-1663.

24. Arfè A, Scotti L, Varas-Lorenzo C et al. Non￾steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ, 2016, 28(354): i4857.

25. Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesu lide is a selective COX-2 inhibitory, atypical non-steroidal antiinflammatory drug. Curr Med Chem, 2008, 15: 278-283.

26. Fanelli A, Romualdi P, Vigano’ R et al. Non-selec tive non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. Acta Biomed, 2013, 84: 1-7.


Просмотров: 121


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)